CSPC Pharmaceutical Group Ltd. has obtained IND clearance from the FDA to conduct clinical trials in the U.S. with SYH-2069 for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.
Neurimmune AG has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, Astrazeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI-009, a fibril depleter for light chain (AL) amyloidosis.
Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies.
Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized xanthine dehydrogenase/oxidase (XDH; XOR) inhibitors reported to be useful for the treatment of hyperuricemia, gout, arthritis and heart failure.
Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have disclosed solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors reported to be useful for the treatment of hyperuricemia, nephropathy and gout.
Genescience Pharmaceuticals Co. Ltd. has divulged thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism, Grave’s disease and thyroid-associated ophthalmopathy (Grave’s ophthalmopathy).
Di’ao Group Chengdu Pharmaceutical Co. Ltd. has identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, dementia, obesity, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD), dyslipidemia, stroke and cardiovascular disorders, among others.
The canonical G protein-coupled receptors (GPCRs) cannabinoid CB1 (CB1R) and CB2 (CB2R) receptors are the most studied in the endocannabinoid system. CB1R is widely distributed throughout the CNS, but is also present on peripheral tissues.
Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have established a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo gene editing program for the treatment of α-1 antitrypsin deficiency (AATD).
Ascletis Pharma Inc. has selected ASC-37 oral tablets as a clinical development candidate for the treatment of obesity. The company expects to submit an IND application to the FDA in the second quarter of next year.
RSS
